brilinta

AstraZeneca’s Brilinta fails to best aspirin in treating stroke patients

pharmafile | March 23, 2016 | News story | Research and Development AstraZeneca, Brilinta, stroke 

AstraZeneca has announced top-line results from the Phase III SOCRATES trial, confirming that twice-daily doses of its drug Brilinta (ticagrelor) failed to best once-daily 100mg aspirin in treating patients with acute ischaemic stroke or transient ischaemic attack (TIA).

The primary efficacy endpoint of the trial was time to first occurrence of any event from the composite of stroke (ischaemic or haemorrhagic), myocardial infarction (MI, also known as heart attack) and death.

Although fewer events were observed in patients on Brilinta (marketed as Brilique in Europe), the trend did not reach statistical significance.

Sean Bohen, executive vice president, Global Medicines Development and chief medical officer at AstraZeneca, says: “We will present the full analysis of the trial results, including subgroups, at a forthcoming stroke congress and will engage with regulatory agencies on the interpretation of the data. The SOCRATES trial enrolled a patient population that differs from the currently-approved indications for Brilinta/Brilique.”

Joel Levy

Related Content

AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer

AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that …

FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment

AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …

FDA approves AstraZeneca’s Ultomiris for NMOSD treatment

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) …

Latest content